A new Cochrane review has cast a critical eye over the growing global interest in stem cell injections for knee osteoarthritis, highlighting significant gaps in current evidence and calling for cautious optimism as further research unfolds.
The review, led by Dr Sam Whittle, a senior consultant rheumatologist from Adelaide’s Queen Elizabeth Hospital, provides a timely analysis of an increasingly popular yet controversial treatment. Knee osteoarthritis affects over 2 million Australians and costs the health system more than $4 billion annually — figures that continue to climb as Australia’s population ages.
Stem Cells: Promise or Premature Hype?
Stem cell therapies have been widely promoted for their theoretical regenerative properties. In principle, stem cells could rebuild cartilage, repair joint structure, and potentially reverse the damage caused by osteoarthritis. However, Dr Whittle stresses that, despite the excitement, real-world evidence remains inconsistent.
READ MORE: MD Anderson Trials Show Breakthrough Results at AACR Annual Meeting 2025
“Stem cells are a special type of cell that can develop into mature cells across different body tissues, including cartilage, bone, and fat,” explains Dr Whittle. “In theory, they could be transformative for joint damage. But so far, results from clinical trials have been mixed, leading to confusion among both clinicians and patients.”
Over 40 systematic reviews have previously examined stem cell injections for knee osteoarthritis, yielding results that range from highly positive to neutral or even negative. Recognising the need for clarity, the Cochrane research team embarked on creating a definitive ‘living review’ — a continually updated resource that will incorporate new evidence every three months.
Key Findings from the Cochrane Review
The Cochrane team analyzed 25 studies involving 1,341 participants, including eight placebo-controlled studies with 459 participants. The trials spanned a wide geographical area, including Europe, Asia, the United States, the Middle East, South America, the United Kingdom, and Australia.
Here are the key conclusions:
- Minor Improvements in Pain and Function:
Stem cell injections may provide small improvements in pain and knee function compared with placebo injections. However, these improvements are modest and of unclear clinical significance. - No Major Impact on Quality of Life:
The review found no convincing evidence that stem cell injections meaningfully improved patients’ overall quality of life or delivered substantial treatment success. - Unclear Structural Benefits:
Despite claims that stem cells might regenerate joint tissue, the review found insufficient evidence to confirm that they alter disease progression or improve knee joint structures. - Safety Data Remains Limited:
While serious adverse events were infrequently reported, the long-term risks of cell-based therapies — including concerns about uncontrolled cell growth — remain unknown. - Methods Matter, but Best Approaches Unclear:
There is still no consensus on the most effective techniques for stem cell harvest, isolation, expansion, storage, or injection. Differences in methodologies across studies complicate efforts to reach definitive conclusions.
Persistent Uncertainty, But Hope Ahead
The Cochrane researchers conclude that significant uncertainty persists regarding the overall benefit and potential harms of stem cell injections. Dr Whittle points to the challenges posed by inconsistent study designs and reporting standards, which have undermined the reliability of earlier findings.
“Across all our results, we can see there remains a great deal of uncertainty around the benefits and harms of stem cell injections, and low certainty in the evidence,” says Dr Whittle. “This ongoing uncertainty is frustrating for everyone wanting to find and access the most effective treatments, and ultimately a cure for this condition.”
However, the future may bring clarity. Several major clinical trials — including a large Australian study based in Sydney — are currently underway. The results from these trials are expected to double the available meta-analysis data within the next few years, potentially transforming the evidence landscape.
“Our living review team will be screening for new evidence every three months from here on in,” says Dr Whittle. “As we accrue those important, large, well-conducted trials, we should get much higher confidence in our estimate of effect, and ideally some more concrete conclusions as results come in over the next two to five years.”
Looking Ahead: Evidence-Based Caution
The Cochrane review underlines the importance of caution among healthcare professionals, patients, funders, and policymakers regarding stem cell treatments. With many procedures currently offered at high out-of-pocket costs — often without strong scientific backing — it is crucial that treatment decisions are guided by the best available evidence.
“Stem cell therapy for knee osteoarthritis remains an exciting but as yet unproven frontier,” says Dr Whittle. “As research continues, we look forward to incorporating new findings that can help inform clearer guidance, policy, and decision making.”
Until then, patients considering stem cell injections should do so with a full understanding of the current uncertainties — and with careful consultation with their healthcare providers.
About the Author
Shauna Hurley is a freelance writer and science communications adviser for Cochrane Australia.
